0 XP   0   0   0

CymaBay Therapeutics Inc
Buy, Hold or Sell?

Should you buy, hold or sell Cymabay?

I guess you are interested in CymaBay Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Cymabay

Let's start. I'm going to help you getting a better view of CymaBay Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is CymaBay Therapeutics Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how CymaBay Therapeutics Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value CymaBay Therapeutics Inc. The closing price on 2023-02-03 was €7.6 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
CymaBay Therapeutics Inc Daily Candlestick Chart
CymaBay Therapeutics Inc Daily Candlestick Chart
Summary









1. Valuation of Cymabay




Current price per share

€7.60

2. Growth of Cymabay




Is Cymabay growing?

Current yearPrevious yearGrowGrow %
How rich?$60.1m$116.1m-$20.3m-21.3%

How much money is Cymabay making?

Current yearPrevious yearGrowGrow %
Making money-$26.4m-$19.7m-$6.6m-25.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cymabay




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of CymaBay Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cymabay earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CymaBay Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y--450.1%+450.1%
10Y--541.0%+541.0%
1.1.2. Return on Assets

Shows how efficient Cymabay is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • -15.4% Return on Assets means that Cymabay generated €-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CymaBay Therapeutics Inc:

  • The MRQ is -15.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.4%TTM-14.4%-1.0%
TTM-14.4%YOY-15.3%+0.9%
TTM-14.4%5Y-12.6%-1.8%
5Y-12.6%10Y-12.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.4%-9.9%-5.5%
TTM-14.4%-8.9%-5.5%
YOY-15.3%-9.3%-6.0%
5Y-12.6%-11.7%-0.9%
10Y-12.6%-12.7%+0.1%
1.1.3. Return on Equity

Shows how efficient Cymabay is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • -40.7% Return on Equity means Cymabay generated €-0.41 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CymaBay Therapeutics Inc:

  • The MRQ is -40.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -29.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-40.7%TTM-29.9%-10.9%
TTM-29.9%YOY-18.1%-11.7%
TTM-29.9%5Y-18.6%-11.3%
5Y-18.6%10Y-18.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-40.7%-12.0%-28.7%
TTM-29.9%-11.5%-18.4%
YOY-18.1%-10.8%-7.3%
5Y-18.6%-14.2%-4.4%
10Y-18.6%-15.2%-3.4%

1.2. Operating Efficiency of CymaBay Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cymabay is operating .

  • Measures how much profit Cymabay makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CymaBay Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y--454.0%+454.0%
10Y--537.1%+537.1%
1.2.2. Operating Ratio

Measures how efficient Cymabay is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of CymaBay Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y-5.132-5.132
10Y-6.371-6.371

1.3. Liquidity of CymaBay Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cymabay is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.20 means the company has €12.20 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of CymaBay Therapeutics Inc:

  • The MRQ is 12.204. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.388. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.204TTM12.388-0.184
TTM12.388YOY13.779-1.391
TTM12.3885Y13.780-1.392
5Y13.78010Y13.7800.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2045.117+7.087
TTM12.3885.755+6.633
YOY13.7795.854+7.925
5Y13.7806.511+7.269
10Y13.7806.222+7.558
1.3.2. Quick Ratio

Measures if Cymabay is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • A Quick Ratio of 9.65 means the company can pay off €9.65 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CymaBay Therapeutics Inc:

  • The MRQ is 9.655. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.492. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.655TTM7.492+2.162
TTM7.492YOY8.614-1.121
TTM7.4925Y8.668-1.175
5Y8.66810Y8.6680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.6554.284+5.371
TTM7.4924.664+2.828
YOY8.6144.787+3.827
5Y8.6685.218+3.450
10Y8.6685.182+3.486

1.4. Solvency of CymaBay Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cymabay assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cymabay to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.62 means that Cymabay assets are financed with 62.2% credit (debt) and the remaining percentage (100% - 62.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CymaBay Therapeutics Inc:

  • The MRQ is 0.622. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.491. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.622TTM0.491+0.131
TTM0.491YOY0.129+0.363
TTM0.4915Y0.220+0.271
5Y0.22010Y0.2200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6220.278+0.344
TTM0.4910.277+0.214
YOY0.1290.306-0.177
5Y0.2200.367-0.147
10Y0.2200.403-0.183
1.4.2. Debt to Equity Ratio

Measures if Cymabay is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cymabay to the Biotechnology industry mean.
  • A Debt to Equity ratio of 164.6% means that company has €1.65 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CymaBay Therapeutics Inc:

  • The MRQ is 1.646. The company is just able to pay all its debts with equity.
  • The TTM is 1.048. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.646TTM1.048+0.598
TTM1.048YOY0.163+0.885
TTM1.0485Y0.405+0.643
5Y0.40510Y0.4050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6460.315+1.331
TTM1.0480.317+0.731
YOY0.1630.319-0.156
5Y0.4050.403+0.002
10Y0.4050.462-0.057

2. Market Valuation of CymaBay Therapeutics Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Cymabay generates.

  • Above 15 is considered overpriced but always compare Cymabay to the Biotechnology industry mean.
  • A PE ratio of -13.13 means the investor is paying €-13.13 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CymaBay Therapeutics Inc:

  • The EOD is -28.347. Company is losing money. -2
  • The MRQ is -13.129. Company is losing money. -2
  • The TTM is -10.239. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-28.347MRQ-13.129-15.218
MRQ-13.129TTM-10.239-2.890
TTM-10.239YOY-18.089+7.850
TTM-10.2395Y-16.820+6.581
5Y-16.82010Y-16.8200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-28.347-8.986-19.361
MRQ-13.129-9.792-3.337
TTM-10.239-16.243+6.004
YOY-18.089-20.876+2.787
5Y-16.820-16.665-0.155
10Y-16.820-14.732-2.088
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Cymabay.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of CymaBay Therapeutics Inc:

  • The MRQ is -11.984. Very Bad. -2
  • The TTM is -10.496. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-11.984TTM-10.496-1.488
TTM-10.496YOY-24.410+13.914
TTM-10.4965Y-18.778+8.282
5Y-18.77810Y-18.7780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.984-0.032-11.952
TTM-10.4960.004-10.500
YOY-24.4100.016-24.426
5Y-18.7780.006-18.784
10Y-18.7780.003-18.781

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cymabay is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.35 means the investor is paying €5.35 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of CymaBay Therapeutics Inc:

  • The EOD is 11.543. Seems overpriced? -1
  • The MRQ is 5.346. Seems overpriced? -1
  • The TTM is 3.156. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD11.543MRQ5.346+6.197
MRQ5.346TTM3.156+2.190
TTM3.156YOY2.972+0.185
TTM3.1565Y2.559+0.597
5Y2.55910Y2.5590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.5431.835+9.708
MRQ5.3462.006+3.340
TTM3.1562.774+0.382
YOY2.9723.453-0.481
5Y2.5592.713-0.154
10Y2.5592.402+0.157
2. Total Gains per Share

2.4. Latest News of CymaBay Therapeutics Inc

Does CymaBay Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from CymaBay Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2023-01-17
14:50
Here's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price StrengthRead

3. Summary

3.1. Key Performance Indicators

The key performance indicators of CymaBay Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.244-0.074-70%-0.190-22%0.051-581%0.051-581%
Book Value Growth--0.7300.958-24%0.864-16%0.916-20%0.916-20%
Book Value Per Share--0.6581.047-37%1.271-48%1.468-55%1.468-55%
Book Value Per Share Growth--0.7300.958-24%0.864-16%0.916-20%0.916-20%
Current Ratio--12.20412.388-1%13.779-11%13.780-11%13.780-11%
Debt To Asset Ratio--0.6220.491+27%0.129+383%0.220+183%0.220+183%
Debt To Equity Ratio--1.6461.048+57%0.163+908%0.405+307%0.405+307%
Dividend Per Share----0%-0%-0%-0%
Eps---0.268-0.290+8%-0.217-19%-0.232-13%-0.232-13%
Eps Growth--1.0960.976+12%0.802+37%0.972+13%0.972+13%
Free Cash Flow Per Share---0.192-0.218+14%-0.1920%-0.194+1%-0.194+1%
Free Cash Flow Per Share Growth--1.2230.907+35%0.723+69%0.941+30%0.941+30%
Free Cash Flow To Equity Per Share---0.1920.109-275%-0.127-34%-0.074-62%-0.074-62%
Free Cash Flow To Equity Per Share Growth--1.223-3.462+383%1.022+20%-0.414+134%-0.414+134%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.415--------
Intrinsic Value_10Y_min---9.275--------
Intrinsic Value_1Y_max---0.684--------
Intrinsic Value_1Y_min---0.887--------
Intrinsic Value_3Y_max---1.719--------
Intrinsic Value_3Y_min---2.719--------
Intrinsic Value_5Y_max---2.348--------
Intrinsic Value_5Y_min---4.593--------
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio11.543+54%5.3463.156+69%2.972+80%2.559+109%2.559+109%
Pe Ratio-28.347-116%-13.129-10.239-22%-18.089+38%-16.820+28%-16.820+28%
Peg Ratio---11.984-10.496-12%-24.410+104%-18.778+57%-18.778+57%
Price Per Share7.600+54%3.5202.945+20%3.739-6%3.350+5%3.350+5%
Price To Total Gains Ratio-31.179-116%-14.441-7.223-50%-20.621+43%-16.715+16%-16.715+16%
Profit Growth--1.0960.976+12%0.802+37%0.972+13%0.972+13%
Quick Ratio--9.6557.492+29%8.614+12%8.668+11%8.668+11%
Return On Assets---0.154-0.144-6%-0.1530%-0.126-18%-0.126-18%
Return On Equity---0.407-0.299-27%-0.181-55%-0.186-54%-0.186-54%
Total Gains Per Share---0.244-0.074-70%-0.190-22%0.051-581%0.051-581%
Total Gains Per Share Growth--1.1061.466-25%0.757+46%1.046+6%1.046+6%
Usd Book Value--60165130.93595717776.375-37%116101166.455-48%134101085.580-55%134101085.580-55%
Usd Book Value Change Per Share---0.263-0.079-70%-0.205-22%0.055-581%0.055-581%
Usd Book Value Per Share--0.7101.130-37%1.371-48%1.584-55%1.584-55%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.289-0.313+8%-0.234-19%-0.251-13%-0.251-13%
Usd Free Cash Flow---17529250.568-19921238.932+14%-17519002.7600%-13821889.710-21%-13821889.710-21%
Usd Free Cash Flow Per Share---0.207-0.235+14%-0.2070%-0.210+1%-0.210+1%
Usd Free Cash Flow To Equity Per Share---0.2070.118-275%-0.138-34%-0.079-62%-0.079-62%
Usd Price Per Share8.201+54%3.7983.178+20%4.035-6%3.615+5%3.615+5%
Usd Profit---24499759.606-26472087.733+8%-19797265.449-19%-21229843.642-13%-21229843.642-13%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.263-0.079-70%-0.205-22%0.055-581%0.055-581%
 EOD+2 -3MRQTTM+14 -20YOY+8 -265Y+10 -2410Y+10 -24

3.2. Fundamental Score

Let's check the fundamental score of CymaBay Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-28.347
Price to Book Ratio (EOD)Between0-111.543
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than19.655
Current Ratio (MRQ)Greater than112.204
Debt to Asset Ratio (MRQ)Less than10.622
Debt to Equity Ratio (MRQ)Less than11.646
Return on Equity (MRQ)Greater than0.15-0.407
Return on Assets (MRQ)Greater than0.05-0.154
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of CymaBay Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5075.349
Ma 20Greater thanMa 506.390
Ma 50Greater thanMa 1005.145
Ma 100Greater thanMa 2004.280
OpenGreater thanClose7.600
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets159,247
Total Liabilities99,069
Total Stockholder Equity60,178
 As reported
Total Liabilities 99,069
Total Stockholder Equity+ 60,178
Total Assets = 159,247

Assets

Total Assets159,247
Total Current Assets155,124
Long-term Assets155,124
Total Current Assets
Cash And Cash Equivalents 30,691
Short-term Investments 122,724
Other Current Assets 668
Total Current Assets  (as reported)155,124
Total Current Assets  (calculated)154,083
+/- 1,041
Long-term Assets
Property Plant Equipment 1,042
Other Assets 3,081
Long-term Assets  (as reported)4,123
Long-term Assets  (calculated)4,123
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,711
Long-term Liabilities86,358
Total Stockholder Equity60,178
Total Current Liabilities
Accounts payable 479
Total Current Liabilities  (as reported)12,711
Total Current Liabilities  (calculated)479
+/- 12,232
Long-term Liabilities
Long term Debt 86,152
Capital Lease Obligations Min Short Term Debt845
Long-term Liabilities  (as reported)86,358
Long-term Liabilities  (calculated)86,997
+/- 639
Total Stockholder Equity
Common Stock8
Other Stockholders Equity -574
Total Stockholder Equity (as reported)60,178
Total Stockholder Equity (calculated)-566
+/- 60,744
Other
Capital Stock8
Common Stock Shares Outstanding 84,678
Net Debt 55,461
Net Invested Capital 146,330
Net Tangible Assets 60,178
Net Working Capital 142,413



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
231,800
205,727
188,600
176,597
168,486
153,825
136,682
117,041
122,902
202,318
200,642
177,724
159,247
159,247177,724200,642202,318122,902117,041136,682153,825168,486176,597188,600205,727231,800
   > Total Current Assets 
227,771
202,923
185,949
174,102
166,129
151,585
133,273
113,813
119,576
191,099
192,046
166,611
155,124
155,124166,611192,046191,099119,576113,813133,273151,585166,129174,102185,949202,923227,771
       Cash And Cash Equivalents 
43,462
24,869
56,794
96,051
47,273
28,193
43,326
32,897
68,963
125,806
73,995
52,753
30,691
30,69152,75373,995125,80668,96332,89743,32628,19347,27396,05156,79424,86943,462
       Short-term Investments 
175,132
166,076
119,438
72,856
113,991
118,130
82,132
73,237
44,825
60,729
114,564
111,130
122,724
122,724111,130114,56460,72944,82573,23782,132118,130113,99172,856119,438166,076175,132
       Net Receivables 
509
687
377
209
284
277
265
227
69
0
0
0
0
000069227265277284209377687509
       Other Current Assets 
7,900
9,910
7,922
4,012
3,761
2,221
5,631
6,060
5,071
2,371
1,384
1,103
668
6681,1031,3842,3715,0716,0605,6312,2213,7614,0127,9229,9107,900
   > Long-term Assets 
4,029
2,804
2,651
2,495
2,357
2,240
3,409
3,228
3,326
11,219
8,596
11,113
4,123
4,12311,1138,59611,2193,3263,2283,4092,2402,3572,4952,6512,8044,029
       Property Plant Equipment 
2,768
2,644
2,491
2,335
2,197
2,033
1,963
1,781
1,605
1,432
1,263
1,213
1,042
1,0421,2131,2631,4321,6051,7811,9632,0332,1972,3352,4912,6442,768
       Long Term Investments 
0
0
0
0
0
0
0
0
0
8,067
4,885
6,874
0
06,8744,8858,067000000000
       Other Assets 
1,261
160
160
160
160
207
1,446
1,447
1,721
1,720
2,448
3,026
3,081
3,0813,0262,4481,7201,7211,4471,4462071601601601601,261
> Total Liabilities 
19,209
19,379
13,552
10,989
11,851
11,119
9,036
9,947
35,844
69,381
93,261
95,267
99,069
99,06995,26793,26169,38135,8449,9479,03611,11911,85110,98913,55219,37919,209
   > Total Current Liabilities 
17,358
17,636
11,922
9,478
10,462
9,857
7,909
8,959
11,741
18,366
14,039
12,560
12,711
12,71112,56014,03918,36611,7418,9597,9099,85710,4629,47811,92217,63617,358
       Accounts payable 
1,494
2,503
1,213
476
947
231
1,606
1,050
764
2,728
199
866
479
4798661992,7287641,0501,6062319474761,2132,5031,494
       Other Current Liabilities 
0
3,193
1,717
879
93
18
0
0
0
0
0
0
0
000000018938791,7173,1930
   > Long-term Liabilities 
1,851
1,743
1,630
1,511
1,389
1,262
1,127
988
24,103
51,015
79,222
82,707
86,358
86,35882,70779,22251,01524,1039881,1271,2621,3891,5111,6301,7431,851
       Capital Lease Obligations Min Short Term Debt
2,240
2,150
2,054
1,954
1,851
1,744
1,629
1,511
1,389
1,262
1,127
988
845
8459881,1271,2621,3891,5111,6291,7441,8511,9542,0542,1502,240
       Other Liabilities 
0
0
0
0
0
0
0
0
23,259
0
0
0
0
000023,25900000000
> Total Stockholder Equity
212,591
186,348
175,048
165,608
156,635
142,706
127,646
107,094
87,058
132,937
107,381
82,457
60,178
60,17882,457107,381132,93787,058107,094127,646142,706156,635165,608175,048186,348212,591
   Common Stock
7
7
7
7
7
7
7
7
7
8
8
8
8
8888777777777
   Retained Earnings Total Equity0000000000000
   Accumulated Other Comprehensive Income 0000000000000
   Capital Surplus 0000000000000
   Treasury Stock0000000000000
   Other Stockholders Equity 
177
80
-130
186
82
8
-6
1
-1
-13
-219
-441
-574
-574-441-219-13-11-6882186-13080177



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-87,582
Operating Income-87,582-87,582
 
Operating Expense (+$)
Research Development64,542
Selling General Administrative23,040
Selling And Marketing Expenses-
Operating Expense87,58287,582
 
Net Interest Income (+$)
Interest Income167
Interest Expense-2,583
Net Interest Income-2,416-2,416
 
Pretax Income (+$)
Operating Income-87,582
Net Interest Income-2,416
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-89,998-87,582
EBIT - interestExpense = -90,165
-89,998
-87,415
Interest Expense2,583
Earnings Before Interest and Taxes (ebit)-87,582-87,415
Earnings Before Interest and Taxes (ebitda)-86,727
 
After tax Income (+$)
Income Before Tax-89,998
Tax Provision--
Net Income From Continuing Ops-89,998-89,998
Net Income-89,998
Net Income Applicable To Common Shares-89,998
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-2,416
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications